Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add: Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
Photolitec to grow with $5M investment
Apr. 18, 2011
 
Photolitec LLC signed a five-year deal with Zhejiang Hisun Pharmaceutical Co. Ltd. The pact includes an initial investment of $2 million, with $1 million in each of the next four years, with additional funding likely based on performance.

Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND
Apr. 18, 2011
 
Apexigen, Inc., announced today that its partner, Simcere Pharmaceutical Group(NYSE: SCR), filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) of China to evaluate APX003 (also known as BD0801) as a potential cancer therapy. APX003 is a humanized monoclonal antibody directed against VEGF, and is intended for the treatment of multiple malignancies.

Pfizer in Deal With Theraclone for Antibody Drug Research
Apr. 18, 2011
 
Pfizer has agreed to pay up to $632 million to Thera-clone Sciences in a research collaboration on antibody drugs for cancer and infectious disease.

Coping biotech medicine attracts more drugmakers
Apr. 18, 2011
 
Worldwide sales of all biologic drugs reached $130billion in 2009, according to IMS health, and industry analysts believe the potential market for biosimilar copies could be worth tens of billions of dollars by the second half of this decade.

A look at the late-stage vaccine pipeline
Apr. 18, 2011
 
In 2009, the world market for preventive vaccines totaled $22.1 billion, up from $19.0
billion in 2008, and is expected to grow at a compound annual rate of 9.7 percent to $35
billion in 2014.

Blockbuster Vaccines of the Future
Apr. 18, 2011
 
The near-term, Phase III vaccine pipeline features potential treatments for addiction,
al-lergy, diabetes and a number of infectious diseases. This list does not include cancer
vac-cines in development, as they will be covered in a separate report.
 
Strategic Partnership Agreement with an institute of Chinese Academy of Sciences
Apr. 30, 2011
 
BravoBio signed a mutual Strategic Partnership Agreement with an institute of Chinese Academy of Sciences this April. Both sides agreed to cooperate in R&D of new emerging diseases. BravoBio will help the institute in industrialization and commercialization of their state-funded research projects, and the institute will support BravoBio with state-of-the art laboratory conditions as well as talent training.
 
BravoBio signed a partnership agreement with a biopharm
Jun. 10, 2011
 
On Jun 10, 2011, BravoBio signed a partnership agreement with a Beijing-based biopharm firm to set up a joint-venture focused in R&D, manufacture and marketing of new generation diagnostic reagents against infectious diseases. The JV has a pipeline of more than 10 products and its output value will pass RMB 15 MN in 3 years. BravoBio's VP, Mr. Shi Jin, will be the CEO of this JV.
 
BravoBio attended Next Generation Pharmaceutical Summit
Jul. 12, 2011
 
On Jul 12 to Jul 14, BravoBio attended the Next Generation Pharmaceutical Summit held in Golden Palm Tree Resort & Spa, Kuala Lumpur, Malaysia. The president of BravoBio, Dr. Wu Ke, was invited to be a panelist discussing the impact of China's new GMP on the pharmaceutical industry. GDS International sponsored the delegates.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next